JUNS

Jupiter Neurosciences Inc. (JUNS) | Rumor.io

Jupiter Neurosciences

JUNS

Attention (50-day avg)0%

Attention rank (50-day avg)#962

Bullish sentiment (50-day avg)83%

Price to earnings ratio-0.13

Market capitalization3.3M

Earnings per share-18.7

Dividend yield (TTM)—

Revenue (annual)21.8K

Net income (annual)-8.6M

Social

What share of all stock conversation is about JUNS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% +0

Aug 31

$JUNS has respected $3 as the bottom so far, with a tiny float, potentially due for a nice rally before long, squeeze or news-driven.
$JUNS's stock price has plummeted 29.7% since the filing, with a current price of $2.90, compared to the filing price of $4.12.
$JUNS has a cash reserve of $3 million and is looking for a dead cat bounce, but the market appears to be bearish, with some predicting a further decline to $1 by Friday.

Generated by AI

Sentiment

Of the messages about JUNS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	90% +6.88	78.35% +2.44
Bearish	—	0%	10% -6.88	21.65% -2.44

Bullish· Aug 21

The company's patented, non-racemic MDMA formulation ALA-002 has entered a definitive license agreement with PharmAla, which could lead to significant growth and volatility.
The stock has already shown a 15% profit and is poised for another push, with potential targets of $9.50, $10.50, $12.90, and $15.00.
The low float of 530k and significant news could lead to a 200% gain, making it the second leading gainer and potentially pushing the price to $20 or higher.

Bearish· Aug 21

The asset has seen significant price fluctuations, with some users predicting a return to $0 and others expecting a crash to $4 after a split.
The company's financials are concerning, with negative equity and no cash reserves, making a dilution likely and potentially impacting the stock price.
The asset's low float is highlighted as a risk factor, with one user estimating that a $200 loss is possible due to this characteristic.

Generated by AI

Topics

Of the messages about JUNS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	82.76%	80%	16.38%
Technical Analysis	0%	17.24%	17.14%	10.98%
Analysts	0%	0%	0%	3.04%
Macro	0%	0%	0%	69.18%
Controversies	0%	0%	2.86%	0.39%
Earnings	0%	0%	0%	0.03%

Announcements· Aug 21

Jupiter Neurosciences, Inc. has entered a definitive license agreement with PharmAla Biotech for the exclusive U.S. rights to ALA-002, a patented non-racemic MDMA formulation.
PharmAla has executed a license agreement with Jupiter Neurosciences, demonstrating its ability to monetize its assets directly on attractive terms while retaining meaningful downstream economics.
Resilient Pharmaceuticals has resubmitted a New Drug Application for MDMA-assisted therapy for PTSD to the FDA, representing a constructive development for the regulatory pathway applicable to MDXX-class therapeutics generally.

Technical Analysis· Aug 21

Must hold $8.50 for $JUNS to continue upwards, with targets at $9.50, $10.50, $11.60, and $12.90.
The stock has a potential breakout retest range around $9.4, and is battling its VWAP.
$JUNS has a big downtrend reversal incoming, with support around $7.7 and resistance around $9.1, and could push to $11 and beyond with the right conditions.

Generated by AI

Community

Of the messages about JUNS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	10.34%	12.64%	6.55%
Newcomers	0%	89.66%	87.36%	93.45%

Regulars· Aug 21

The company has received a U.S. patent covering novel enantioselective processes, with PharmAla Biotech providing a corporate update on this development.
The stock has experienced a significant price increase, with some regulars mentioning gains of up to +63% and a recent price of $10.28.
The company has entered a definitive license agreement with PharmAla for its patented, non-racemic MDMA formulation ALA-002, which may have contributed to the stock's recent surge.

Newcomers· Aug 31

Newcomers to the market are expecting a short squeeze or a news-driven rally, with some predicting a price increase to $5+ or even $7.
Investors are concerned about the company's ability to recover from its current price drop of 29.7% since the filing, with some even speculating about the possibility of delisting.
Others are focused on the company's cash reserves, with one user noting that they have 3 months' cash on hand, while another user is looking for a dead cat bounce, but is skeptical about the company's chances of recovery.

Generated by AI

News

12 Health Care Stocks Moving In Tuesday's After-Market Session

14d agoBenzinga

Jupiter Neurosciences Completes Capital Raise Supporting Nasdaq Listing

Detailed price information for Jupiter Neurosciences Inc (JUNS-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

12 Health Care Stocks Moving In Friday's Intraday Session

1mo agoBenzinga

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

New York, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 307,692 shares of common stock in a registered direct offering. The gross proceeds of the offering are approximately $2.0 million (the "Offering"). D. Boral Capital LLC is acti

1mo agoYahoo Finance

Jupiter Neurosciences Stock Surges Friday: What's Driving the Action?

1mo agoBenzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session

1mo agoBenzinga

Also Discussed

Investors talking about JUNS also mention

#	Name	Attention
1	Linkers Industries LimitedLNKS	0%0
2	Generation Income Properties Inc.GIPR	0%0
3	TNL Mediagene Ordinary SharesTNMG	0%new
4	Singularity Future Technology Ltd.SGLY	0%0
5	Nocera, Inc.NCRA	0%new
6	Autonomix Medical Inc.AMIX	0%0
7	Onfolio Holdings, Inc.ONFO	0%-0.05
8	Tenon Medical, Inc.TNON	0%new
9	Gaxos.ai Inc.GXAI	0%0
10	Sadot Group Inc.SDOT	0%new

Jupiter Neurosciences Inc.

Healthcare
Biotechnology

Jupiter Neurosciences Inc. is a clinical-stage pharmaceutical company focused on developing therapies for neuroinflammation, central nervous system disorders, and selected rare diseases. Its work centers on JOTROL, an enhanced oral resveratrol formulation designed for pharmaceutical use across conditions such as Parkinson’s disease, Alzheimer’s disease, and other neurological disorders. The company also operates a premium nutritional supplements segment through the Nugevia brand, which includes consumer products positioned around longevity, cognitive support, and wellness. Jupiter Neurosciences Inc. combines drug development with consumer health offerings, giving it a presence in both the biopharmaceutical and nutritional supplement markets. Headquartered in Jupiter, Florida, the company is organized around research, formulation technology, and commercial product development in the health sciences sector.

Website

Location

1001 North US Highway 1

Jupiter, FL, 33477

United States

Social

What share of all stock conversation is about JUNS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% +0

Aug 31

$JUNS has respected $3 as the bottom so far, with a tiny float, potentially due for a nice rally before long, squeeze or news-driven.
$JUNS's stock price has plummeted 29.7% since the filing, with a current price of $2.90, compared to the filing price of $4.12.
$JUNS has a cash reserve of $3 million and is looking for a dead cat bounce, but the market appears to be bearish, with some predicting a further decline to $1 by Friday.

Generated by AI

Sentiment

Of the messages about JUNS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	90% +6.88	78.35% +2.44
Bearish	—	0%	10% -6.88	21.65% -2.44

Bullish· Aug 21

The company's patented, non-racemic MDMA formulation ALA-002 has entered a definitive license agreement with PharmAla, which could lead to significant growth and volatility.
The stock has already shown a 15% profit and is poised for another push, with potential targets of $9.50, $10.50, $12.90, and $15.00.
The low float of 530k and significant news could lead to a 200% gain, making it the second leading gainer and potentially pushing the price to $20 or higher.

Bearish· Aug 21

The asset has seen significant price fluctuations, with some users predicting a return to $0 and others expecting a crash to $4 after a split.
The company's financials are concerning, with negative equity and no cash reserves, making a dilution likely and potentially impacting the stock price.
The asset's low float is highlighted as a risk factor, with one user estimating that a $200 loss is possible due to this characteristic.

Generated by AI

Topics

Of the messages about JUNS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	82.76%	80%	16.38%
Technical Analysis	0%	17.24%	17.14%	10.98%
Analysts	0%	0%	0%	3.04%
Macro	0%	0%	0%	69.18%
Controversies	0%	0%	2.86%	0.39%
Earnings	0%	0%	0%	0.03%

Announcements· Aug 21

Jupiter Neurosciences, Inc. has entered a definitive license agreement with PharmAla Biotech for the exclusive U.S. rights to ALA-002, a patented non-racemic MDMA formulation.
PharmAla has executed a license agreement with Jupiter Neurosciences, demonstrating its ability to monetize its assets directly on attractive terms while retaining meaningful downstream economics.
Resilient Pharmaceuticals has resubmitted a New Drug Application for MDMA-assisted therapy for PTSD to the FDA, representing a constructive development for the regulatory pathway applicable to MDXX-class therapeutics generally.

Technical Analysis· Aug 21

Must hold $8.50 for $JUNS to continue upwards, with targets at $9.50, $10.50, $11.60, and $12.90.
The stock has a potential breakout retest range around $9.4, and is battling its VWAP.
$JUNS has a big downtrend reversal incoming, with support around $7.7 and resistance around $9.1, and could push to $11 and beyond with the right conditions.

Generated by AI

Community

Of the messages about JUNS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	10.34%	12.64%	6.55%
Newcomers	0%	89.66%	87.36%	93.45%

Regulars· Aug 21

The company has received a U.S. patent covering novel enantioselective processes, with PharmAla Biotech providing a corporate update on this development.
The stock has experienced a significant price increase, with some regulars mentioning gains of up to +63% and a recent price of $10.28.
The company has entered a definitive license agreement with PharmAla for its patented, non-racemic MDMA formulation ALA-002, which may have contributed to the stock's recent surge.

Newcomers· Aug 31

Newcomers to the market are expecting a short squeeze or a news-driven rally, with some predicting a price increase to $5+ or even $7.
Investors are concerned about the company's ability to recover from its current price drop of 29.7% since the filing, with some even speculating about the possibility of delisting.
Others are focused on the company's cash reserves, with one user noting that they have 3 months' cash on hand, while another user is looking for a dead cat bounce, but is skeptical about the company's chances of recovery.

Generated by AI

Jupiter Neurosciences

Social

Aug 31

Bullish· Aug 21

Bearish· Aug 21

Announcements· Aug 21

Technical Analysis· Aug 21

Regulars· Aug 21

Newcomers· Aug 31

12 Health Care Stocks Moving In Tuesday's After-Market Session

Jupiter Neurosciences Completes Capital Raise Supporting Nasdaq Listing

12 Health Care Stocks Moving In Friday's Intraday Session

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

Jupiter Neurosciences Stock Surges Friday: What's Driving the Action?

12 Health Care Stocks Moving In Friday's Pre-Market Session

Also Discussed

Jupiter Neurosciences Inc.

Company Information

Location

12 Health Care Stocks Moving In Tuesday's After-Market Session

Jupiter Neurosciences Completes Capital Raise Supporting Nasdaq Listing

12 Health Care Stocks Moving In Friday's Intraday Session

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

Jupiter Neurosciences Stock Surges Friday: What's Driving the Action?

12 Health Care Stocks Moving In Friday's Pre-Market Session

Also Discussed

Social

Aug 31

Bullish· Aug 21

Bearish· Aug 21

Announcements· Aug 21

Technical Analysis· Aug 21

Regulars· Aug 21

Newcomers· Aug 31